Sector: MedicalCorcept Therapeutics Incorporated (NASDAQ: CORT)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 280 |
Technical : | 60 |
Performance : | 6 |
Overall: | 90 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 283 |
Technical : | 23 |
Performance : | 23 |
Overall: | 80 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 279 |
Technical : | 49 |
Performance : | 4 |
Overall: | 74 |
Number of Stocks: | 306 |
Headlines
- Corcept Therapeutics Announces Recent Highlights and Third Quarter 2009 Financial Results
Nov 10, 2009 09:01 AM | CORT
- Virtual Funds: Financial Fund's Ranking/Performance In Q3 '08 And Overall
Oct 30, 2008 01:48 AM | ASBC, AXP, C, CATY, CBG, CME
- This Week's Insider Buys - Apr 6 2008 1:39PM
Apr 06, 2008 01:39 PM | CHDN, COMS, CORT, CVO, ESC, HERO
- Berkshire Hathaway — The Anti-Volatility Fortress
Mar 01, 2008 06:05 PM | ADAM, AMZN, CLAY, CORT, FISI
- BIOTECH STOCKS: Sector Stocks Rise; Discovery Partners Soars On Partner's Deal
Aug 28, 2006 07:09 PM | CORT, MEDI, SUPG
- Corcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company Through Corlux NDA Submission
Oct 13, 2009 10:53 AM | CORT
- Corcept Therapeutics Announces Second Quarter 2009 Results and Development Highlights
Aug 11, 2009 09:01 AM | CORT
- Corcept Therapeutics Announces First Quarter 2009 Results and Development Highlights
May 11, 2009 09:05 AM | CORT
- Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs
Mar 30, 2009 09:01 AM | CORT
- Data Demonstrates Metabolic Benefits of Adding CORLUX(R) to Treatment With Risperdal(R)
Feb 23, 2009 09:00 AM | CORT
- CORLUX(R) Mitigates Weight Gain Associated With Risperdal(R), Expands on Proof of Concept Established in Earlier Trials
Feb 02, 2009 09:01 AM | CORT
- Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated With Use of Olanzapine -- the Active Ingredient in Zyprexa(R)
Jan 08, 2009 09:01 AM | CORT
- Caroline Loewy Joins Corcept as Chief Financial Officer
Dec 02, 2008 09:01 AM | CORT
- Corcept Therapeutics Announces Third Quarter 2008 Results
Nov 13, 2008 09:01 AM | CORT
- Corcept Therapeutics Continues Collaboration With Eli Lilly and Company
Sep 03, 2008 09:01 AM | CORT
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: COOK JOSEPH C JR (10K)
Oct 21, 2009 02:13 PM
- Form 4/A CORCEPT THERAPEUTICS For: Oct 16 Filed by: CHAMPSI FARAH (10K)
Oct 20, 2009 08:37 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: PENHOET EDWARD (10K)
Oct 20, 2009 06:57 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: CHAMPSI FARAH (10K)
Oct 20, 2009 06:54 PM
- Form 4 SHEEHAN ANDREW T For: Oct 16 (10K)
Oct 20, 2009 06:46 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: COXE TENCH (10K)
Oct 20, 2009 06:38 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: YOUNGER WILLIAM H JR (10K)
Oct 20, 2009 06:38 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: ANDERSON DAVID L (10K)
Oct 20, 2009 06:38 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: BAKER G LEONARD JR (10K)
Oct 20, 2009 06:38 PM
- Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: SWEET DAVID E (10K)
Oct 20, 2009 06:38 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
CORT
|
Compare to S&P
|
| YTD |
101.96 %
|
67.15 %
|
| 4 Weeks |
-23.13 %
|
-23.96 %
|
| 12 Weeks |
80.70 %
|
70.36 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 10.00 %
|
|
EPS Growth in Last Year: 18.18 %
|
|
Sales Growth in Last Quarter: -75.00 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
